A5021613131- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Advanced Breast Cancer Therapies
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Retinoids in leukemia and cellular processes
- Renal Diseases and Glomerulopathies
- Gastrointestinal Tumor Research and Treatment
- Cutaneous lymphoproliferative disorders research
- Immune Cell Function and Interaction
- Kruppel-like factors research
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related Molecular Pathways
- Calcium signaling and nucleotide metabolism
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Federal Almazov North-West Medical Research Centre
2013-2023
Ministry of Health of the Russian Federation
2016-2021
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study characterize course COVID-19 in and identify potential predictors outcome. Of 190 confirmed diagnosed between 28/03/2020 22/05/2020, 151 (79%) presented (need oxygen and/or intensive care admission). Severe was associated advanced...
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphoma. Eligible were aged ≥65 years, <65 years coexisting conditions. Patients received oral 420 mg once daily until disease progression unacceptable toxicity six cycles chlorambucil, each in combination intravenous obinutuzumab. After median follow-up 45 months (range, 0.2-52),...
Abstract Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet need. Though Bruton tyrosine kinase (BTK) and PLCG2 mutations are associated resistance, their frequency relevance to progression not fully understood. In this multicenter retrospective observational study, we analyzed 98 patients CLL (49 relapsing after initial response 49 still responding ≥1 year of continuous treatment) using a next-generation sequencing (NGS) panel (1% sensitivity)...
Background & Aims. New schemes of the antitumor therapy CLL resulted in improvement survival relatively young patients. However, outcomes elderly patients are still unsatisfactory. Erroneous overestimation expected toxicity standard therapeutic regimens some may play a certain role, thus leading to prescription less effective regimens. Therefore, urgent problem is find objective criteria for risk stratification CLL. The aim study evaluate prognostic significance patient's age and CIRS-G...
Aim. To evaluate the efficacy and safety of BR regimen containing bendamustine in patients with chronic lymphocytic leukemia (CLL) who have not previously received specific therapy. Subjects methods. The results Russian prospective observational multicenter study BEN-001 (2012—2015) covering 196 CLL from 34 centers Federation were analyzed. diagnosis was confirmed by peripheral blood lymphocyte immunophenotyping. A centralized approach employed to make IGHV gene mutational status analysis,...
Summary In 2014, an interim analysis of a phase 3 study was performed to evaluate the effectiveness ofatumumab in patients with bulky fludarabine‐refractory chronic lymphocytic leukaemia (BFR CLL) as compared physician’s choice. The five‐year follow‐up this trial showed that therapy resulted numerically but not significantly longer overall survival. As only few had chance receive kinase inhibitor later, displays survival BFR CLL period prior receiving small‐molecule inhibitors. Ofatumumab is...
Aim. To estimate ibrutinib efficacy in the treatment of early CLL relapses and patients with > 2 lines preceding therapy. Analysis results del(17p) monitoring minimal residual disease (MRD) safety profile. Materials & Methods. The analysis included 31 CLL. Twenty eight were treated by bendamustine fludarabine containing regimens. median prior (range 1-10). indications for initiation first relapse 51 % cases (n = 16) a after more therapy 49 15). Ibrutinib was administered mono- 15)...
Background. Current treatment of relapsed/refractory chronic lymphocytic leukemia implies the use regimens that include innovative drugs such as ibrutinib and a combination venetoclax with rituximab. Herewith rituximab provides high rate eradication minimal residual disease and, in contrast to ibrutinib, standard version it is canceled after 2 years from start therapy. Aim. Evaluation cost-effectiveness + ibrutinib. Materials methods. The evaluation was carried out position health care...
This trial has evaluated a systematic prospective analysis of the efficacy and safety BR in CLL patients routine clinical practice. It included 179 with verified diagnosis presence indications for initiation therapy according to guidelines iwCLL who received regimen. The shown that regime high efficiency relatively low toxicity first line also is well tolerated comorbidity impaired renal function. lower IGHV-unmutated type CLL. achieving eradication MRD BM best predictor PFS.
We retrospectively analyzed the effectiveness of ruxolitinib in patients with myelofibrosis (MF) real clinical practice Russia. The study included 42 MF an average age 56 years from 10 inpatient and outpatient clinics. majority (55 %) belonged to intermediate risk group 1 on DIPSS scale, 86 % had massive splenomegaly 88 constitutional symptoms. initial dose was 15 mg twice a day. At time analysis, 74 continued taking duration therapy 20 months. A decrease palpable size spleen by at least 50...
Background & Aims. The IGHV gene mutation status is a constant biological feature of tumor cells in chronic lymphocytic leukemia (CLL). This parameter an important predictor the efficacy immunochemotherapy. It was included into CLL international prognostic index CLL-IPI developed recently. aim to evaluate significance BR regimen patients with different variants B-cell receptor (BCR) structure. Methods. study examined immediate and delayed treatment outcomes for 183 Russian, prospective,...
Background & Aims. Flow cytometry is successfully used for diagnosis of malignant lymphoproliferative disorders. However, there are atypical cases that difficult to interpret; thus, new markers relevant the differential be searched for. The aim analyze CD200 expression in patients with B-cell Materials Methods. 187 chronic lymphocytic leukemia (CLL), 14 mantle cell lymphoma (MCL), 9 marginal zone (MZL), and 5 hairy (HCL) were enrolled study. Neoplasm was not confirmed 12 subjects....
Currently we are facing a revolution in therapy of chronic lymphocytic leukemia, related to the development novel target drugs, which have markedly improved treatment results all groups patients. While inhibitors Bruton’s tyrosine kinase (ibrutinib, acalabrutinib etc.) and phosphatidylinositol-3 isoforms (idelalisib, umbralisib currently spotlight, much less attention is paid antiapoptotic protein such as venetoclax. In this review summarize venetoclax clinical studies CLL monotherapy...